Ionis Pharmaceuticals: cross-border access for the specialty portfolio
Quick orientation
Ionis Pharmaceuticals, Inc. is a US biotechnology company headquartered in Carlsbad, California, and is the pioneer of antisense oligonucleotide (ASO) RNA-targeted therapy. Ionis has more than 40 ASO candidates in clinical or commercial-stage development and has built one of the broadest RNA platforms in the industry. Several Ionis-discovered drugs are marketed by partners under royalty and licensing arrangements - most notably Biogen for the spinal muscular atrophy franchise and AstraZeneca for cardiometabolic candidates. Ionis trades on NASDAQ as IONS. FDA approval scale across Ionis-discovered ASOs includes multiple cardiovascular, neurological, and rare disease products, and the platform continues to deliver clinical candidates into a maturing development pipeline.
Ionis portfolio in cross-border NPP scope
Qalsody (tofersen), partnered with Biogen, is an antisense oligonucleotide approved by the FDA in April 2023 under accelerated approval for the treatment of amyotrophic lateral sclerosis (ALS) in adults with a confirmed superoxide dismutase 1 (SOD1) gene mutation. SOD1-ALS accounts for approximately two percent of all ALS cases. Qalsody is administered by intrathecal injection. The US list price is approximately US$14,230 per vial, with monthly dosing during the maintenance phase after a loading regimen.
Waylivra (volanesorsen) is approved in Europe and the UK for familial chylomicronemia syndrome (FCS) but is not currently FDA-approved in the United States; Reserve Meds therefore does not source Waylivra from US channels.
Tegsedi (inotersen) was previously approved for hereditary transthyretin amyloidosis (hATTR) polyneuropathy but has been withdrawn from major markets following the broader uptake of newer hATTR therapies; we direct hATTR patients to Amvuttra (vutrisiran, Alnylam) where appropriate.
Ionis-discovered SMA franchise drug Spinraza (nusinersen) is commercialised by Biogen and is profiled on the Biogen manufacturer page. Wainua (eplontersen), an Ionis ASO for hATTR polyneuropathy, was FDA-approved in December 2023 and is now commercialised with AstraZeneca.
Why patients route through cross-border NPP
SOD1-ALS is an ultra-rare neurological subtype - global prevalence of SOD1 mutations among ALS patients is roughly one to two percent, meaning the addressable population in any single country is small. Outside the United States, Qalsody is approved by the European Commission (May 2024) and by the UK MHRA, but reimbursement and patient access are uneven across the GCC, India, North Africa, and Southeast Asia. Patients with a confirmed SOD1 genetic test routinely face a registration gap of two to five years between FDA approval and local commercial launch, during which the only viable supply chain is cross-border named patient access from US or European inventory.
Pricing also matters. The annual cost of Qalsody is substantial, and patients or families in jurisdictions with limited orphan-drug reimbursement frequently self-pay through private channels. Reserve Meds' cross-border NPP route delivers verified US-sourced commercial product at transparent landed cost. Patient profile is typically: confirmed SOD1 mutation, ALS Functional Rating Scale-Revised (ALSFRS-R) score that justifies treatment per the prescribing neurologist, intrathecal access available at the local site, and family or self-pay capacity for ongoing monthly dosing.
Common cross-border destinations
The highest-frequency NPP destinations for Ionis-discovered products from US-approved inventory are the United Arab Emirates, Saudi Arabia, India, Qatar, and Turkey. Major ALS clinical centers in Dubai, Riyadh, Mumbai, Bangalore, and Istanbul are common referral sources where SOD1 mutation testing has been performed and confirmed but local Qalsody supply is unavailable.
Manufacturer engagement posture
Reserve Meds coordinates Ionis-discovered, partner-commercialised product through DSCSA-compliant US specialty distributors. We are not affiliated with Ionis or its commercial partners (Biogen, AstraZeneca, Novartis, and others). Our role is patient-facing coordination for named individual patients with a verified prescription. For Ionis medical affairs or partner medical affairs teams interested in cross-border NPP pathways for SOD1-ALS or other rare-disease patient populations, our BD contact is [email protected].
What Reserve Meds provides
For each Ionis-discovered product request, Reserve Meds coordinates: prescription verification with the treating neurologist or specialist; DSCSA serialized chain-of-custody from manufacturer or partner distribution through licensed US wholesalers to the named patient; cold-chain shipping where required, with temperature data-loggers and remediation protocols; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator who manages each shipment from prescription to delivery.
Clinical governance and prescription review
Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.
Supply chain integrity
Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.
Destination-country regulatory pathways
Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.
What to expect through the coordination process
Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.
Not affiliated with the manufacturer
Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.
Privacy and data handling
Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.
Next step for patients
Patients or caregivers with a confirmed SOD1 mutation and a treating-physician prescription for Qalsody can begin a request now. Start a Qalsody request ›
For other Ionis-discovered products, please use our general request form and note the product name. Start a request ›
Next step for Ionis teams
Ionis or partner medical affairs and access teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected]. We coordinate named-patient export of FDA-approved Ionis-discovered commercial product through US specialty wholesale channels with full chain-of-custody.
Reserved for you.